Graves’ Disease Following COVID-19 Vaccination: A Population-based, Matched Case-control Study
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgad582 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Alexander Gorshtein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Institute, Rabin Medical Center-Beilinson Hospital, Petach Tikva, 4941492, Israel. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Graves Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Objective
Multiple cases and case series reported Graves’ disease (GD) following coronavirus disease 2019 (COVID-19) vaccination. We aimed to determine whether COVID-19 vaccination was associated with the incidence of GD.
Methods
We analyzed data from Clalit Health Services, the largest healthcare organization in Israel, which insures 4.7 million patients. A population-based, matched, case-control study was performed. Cases were defined as adult patients diagnosed with GD between December 2020 and November 2022. Each case was matched with controls in a 1:2 ratio. Each control was assigned an index date, which was identical to that of their matched case, defined as the date of GD diagnosis. Time between vaccination date and the diagnosis of GD or index date was assessed.
Results
A total of 726 patients with GD were matched with 1452 controls. The study patients and controls have received similar proportions of the COVID-19 vaccine [at least 1 dose: 80% (581/726) vs 77.8% (1129/1452), P = .22, respectively]. In a univariate analysis, at least 1 dose of the COVID-19 vaccine was not associated with the incidence of GD [odds ratio 95% confidence interval: 1.15 (.92-1.43)]. The mean time between first COVID-19 vaccination and the diagnosis of GD for cases or index date for controls was not significantly different [275.69 days (SD 144.37) for cases compared to 275.45 days (SD 145.76) for controls].
Conclusion
Our study found no association between COVID-19 vaccination and the incidence of GD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrine Institute, Rabin Medical Center-Beilinson Hospital, Petach Tikva, 4941492, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel.
- Research Authority, Rabin Medical Center-Beilinson Hospital, Petach Tikva, 4941492, Israel.
ORCID-Profile: Alexander Gorshtein, Adi Turjeman, Hadar Duskin-Bitan, Leonard Leibovici, Eyal Robenshtok
Zitieren
APA
Gorshtein, A., Turjeman, A., Duskin-Bitan, H., Leibovici, L., & Robenshtok, E. (2024). Graves’ Disease Following COVID-19 Vaccination: A Population-based, Matched Case-control Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad582
Vancouver
Gorshtein A, Turjeman A, Duskin-Bitan H, Leibovici L, Robenshtok E. Graves’ Disease Following COVID-19 Vaccination: A Population-based, Matched Case-control Study. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad582
BibTeX
@article{Gorshtein2024,
author = {Gorshtein, Alexander and Turjeman, Adi and Duskin-Bitan, Hadar and Leibovici, Leonard and Robenshtok, Eyal},
title = {Graves’ Disease Following COVID-19 Vaccination: A Population-based, Matched Case-control Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgad582}
}
EUVIMED